Clinical Trials

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT04443348 2025-10-14

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

120 enrolled

Triple Negative Breast Neoplasms

NCT05645380 2025-10-07

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04083963 2025-07-10

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

13 enrolled

Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

146 enrolled

Triple Negative Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

185 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03164993 2024-10-15

ALICE

68 enrolled

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

70 enrolled

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

24 enrolled 17 charts

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

182 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

82 enrolled

Triple Negative Breast Neoplasms

NCT02768701 2023-05-22

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

40 enrolled 17 charts

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

280 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04771871 2022-02-18

TARMAC

42 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT02183805 2021-07-23

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

Phase 2 Terminated

6 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02413320 2021-05-10

NeoSTOP

101 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03289819 2021-04-08

NIB

53 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04676997 2020-12-21

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

20 enrolled

Triple Negative Breast Neoplasms

NCT04437160 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

286 enrolled

Triple Negative Breast Neoplasms

NCT02789332 2020-03-17

GeparOla

107 enrolled

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01306032 2017-04-26

Phase II ABT-888 With Cyclophosphamide

124 enrolled 21 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01910844 2016-10-11

META2

Phase 2 Terminated

3 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

164 enrolled

Triple Negative Breast Neoplasms

NCT01969032 2014-11-05

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

41 enrolled